SeaCrest Wealth Management LLC Makes New $36,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

SeaCrest Wealth Management LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,400 shares of the company’s stock, valued at approximately $36,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VIR. Nisa Investment Advisors LLC increased its holdings in shares of Vir Biotechnology by 127.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $25,000 after purchasing an additional 560 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in shares of Vir Biotechnology by 5.4% in the first quarter. Handelsbanken Fonder AB now owns 11,800 shares of the company’s stock valued at $303,000 after purchasing an additional 600 shares during the last quarter. US Bancorp DE increased its holdings in shares of Vir Biotechnology by 175.1% in the second quarter. US Bancorp DE now owns 982 shares of the company’s stock valued at $25,000 after purchasing an additional 625 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Vir Biotechnology by 6.8% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,983 shares of the company’s stock valued at $257,000 after purchasing an additional 635 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Vir Biotechnology by 1.4% in the first quarter. Rhumbline Advisers now owns 64,769 shares of the company’s stock valued at $1,666,000 after purchasing an additional 915 shares during the last quarter. 64.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on VIR. SVB Leerink upped their price objective on shares of Vir Biotechnology from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, November 4th. Needham & Company LLC decreased their price target on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. Barclays decreased their price target on shares of Vir Biotechnology to $67.00 in a research note on Monday, August 15th. Morgan Stanley upped their price target on shares of Vir Biotechnology from $15.00 to $18.00 and gave the company an “underweight” rating in a research note on Friday, November 4th. Finally, TheStreet upgraded shares of Vir Biotechnology from a “d” rating to a “c-” rating in a research note on Monday, October 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $52.50.

Insider Buying and Selling

In other news, major shareholder Endurance (Cayman) Ltd Svf sold 132,978 shares of the stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $27.22, for a total value of $3,619,661.16. Following the completion of the transaction, the insider now owns 21,953,302 shares of the company’s stock, valued at $597,568,880.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Endurance (Cayman) Ltd Svf sold 132,978 shares of the stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $27.22, for a total value of $3,619,661.16. Following the completion of the transaction, the insider now owns 21,953,302 shares of the company’s stock, valued at $597,568,880.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of the stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $20.67, for a total transaction of $370,303.05. Following the completion of the transaction, the director now directly owns 1,416,919 shares of the company’s stock, valued at approximately $29,287,715.73. The disclosure for this sale can be found here. Insiders sold 236,896 shares of company stock valued at $6,248,057 over the last quarter. 22.40% of the stock is owned by company insiders.

Vir Biotechnology Stock Down 1.2 %

VIR opened at $26.70 on Tuesday. Vir Biotechnology, Inc. has a twelve month low of $18.05 and a twelve month high of $58.00. The company has a 50-day simple moving average of $22.09 and a 200 day simple moving average of $24.44. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 3.18 and a beta of -0.01.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Articles

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.